1. Introduction {#sec1}
===============

Inflammatory arthritis is a group of complex diseases, including rheumatoid arthritis (RA), psoriatic arthritis (PsA), juvenile idiopathic arthritis (JIA), etc. And it is characterized by inflammatory cell infiltration into the joints \[[@B1], [@B2]\]. There is no doubt that environmental factors and genetic factors play an important role in the development of inflammatory arthritis.

MicroRNAs (miRNAs) are small noncoding RNAs, which are about 22 nucleotides long. They play an important role in regulating transcription and translation \[[@B3]--[@B6]\]. Some studies indicated that they also participate in cell proliferation, differentiation, and apoptosis \[[@B7], [@B8]\]. And, miRNAs can cause the degradation or translation repression of their target miRNA by binding to the 3′-untranslated region of specific mRNAs (messenger RNAs) \[[@B9]--[@B12]\]. Recently, some studies reported that miRNA may associate with inflammatory arthritis, such as miRNA-146 rs2910164 and miRNA-499 rs3746444. Therefore, we chose miRNA-146 rs2910164 and miRNA-499 rs3746444 to explore the association between its polymorphisms and inflammatory arthritis.

MiRNA-146 is located on human chromosome 5q34 and related to immune regulation, inflammatory signaling pathway, because it can regulate the expression of IL-1 receptor-associated kinase (IRAK1) and IRAK2 and targets TNF receptor-associated factor 6 (TRAF6) \[[@B13]\]. And, miRNA-499 is related to the expression of Interleukin-17 receptor B (IL-17RB), IL-2RB, IL-6, B and T lymphocyte attenuator (BTLA), and peptidyl arginine deiminase 4 (PADI4) \[[@B14]\]. Both miRNA-146 and miRNA-499 are thought to be involved in autoimmune and inflammatory diseases \[[@B15]\].

Considering the results of miRNA-146 and miRNA-499 polymorphisms with inflammatory arthritis are inconsistent \[[@B16]--[@B20]\], this discrepancy might be caused by some studies that have small sample size, low statistical power, ethnicity differences, and publication bias. It is necessary to conduct meta-analysis to explore this association.

2. Methods {#sec2}
==========

2.1. Search Strategy {#sec2.1}
--------------------

A systematic search of studies on the association of miRNA-146 and miRNA-499 polymorphisms with inflammatory arthritis susceptibility was conducted in PubMed, Web of science, Elsevier ScienceDirect, and Cochrane Library. Keywords for the search were as follows: ("microRNA" or "miRNA" or "microRNAs") and ("Inflammatory arthritis") and ("polymorphism" or "variant" or "genotype" or "SNP" or "mutations"). All relevant studies were retrieved. We screened those studies by reading its titles, abstracts, and contents carefully.

2.2. Eligibility Criteria {#sec2.2}
-------------------------

The inclusion criteria were (i) studies involving the association between miRNA gene polymorphisms and inflammatory arthritis; (ii) case-control study; (iii) studies based on human; (iv) studies providing the detailed relevant genotype data of both case group and control group. Studies were excluded if (i) the study was a review, editorial, abstract, case report, or unpublished article; (ii) studies were nonhuman studies or animal experiments or cell experiments; (iii) studies had no controls or no detailed relevant genotype data.

2.3. Data Extraction {#sec2.3}
--------------------

The data of the eligible studies were extracted by one investigator (Mr.Wang). The following information were collected: first author\'s name; year of publication; type of disease; country; region; genotyping methods; number of cases and controls in each study; characteristics of controls; category of polymorphisms and other additional information.

2.4. Quality Assessment {#sec2.4}
-----------------------

The included studies in this meta-analysis were evaluated by another inspector (Pan). The quality assessment was based on the modified Newcastle-Ottawa Quality Assessment Scale (NOS). The scale consists of eight multiple-choice questions that involve subjects\' selection, comparability in cases and controls, and assessment of exposure. High-quality response earns a point, totaling up to nine points (the comparability question earns up to two points). The higher score indicates better quality.

2.5. Statistical Analysis {#sec2.5}
-------------------------

All statistical analyses were performed by Stata 12.0 (StataCorp, College Station, TX, USA) software. OR and 95% CI were used to evaluate the strength of association between miRNA-146/499 polymorphisms with inflammatory arthritis susceptibility under different genetic models. The effect of heterogeneity was evaluated using *I*^2^ statistics. Heterogeneity was recognized as statistically significant when *I*^2^ \> 50%. According to the value of *I*^2^, we chose fixed-effects or random-effects model. All subgroups were analyzed. Sensitivity analysis was used to evaluate the influence of individual study on the overall OR. Publication bias was assessed by Funnel\'s plot, Begg\'s test and Egger\'s test. An asymmetric plot and the *P* value of Egger\'s test or Begg\'s test less than 0.05 were considered as significant publication bias.

3. Results {#sec3}
==========

3.1. Literature Search {#sec3.1}
----------------------

A total of 390 studies were retrieved from PubMed, Web of science, Elsevier Science Direct and Cochrane Library. Finally, 18 eligible studies were included in this meta-analysis. A flowchart of the included and excluded studies was shown in [Figure 1](#fig1){ref-type="fig"}.

3.2. Characteristics of the Included Studies {#sec3.2}
--------------------------------------------

[Table 1](#tab1){ref-type="table"} showed the main features of those included studies. Those studies were all English articles, which have been published from 2010 to 2018. All studies included in this meta-analysis were case-control studies. Eighteen studies involving 3385 inflammatory arthritis patients and 4584 controls were included in this meta-analysis.

3.3. Meta-Analysis of Association between miRNA-146 rs2910164 Polymorphism and Inflammatory Arthritis {#sec3.3}
-----------------------------------------------------------------------------------------------------

Meta-analysis indicated that there is lack of association between miRNA-146 rs2910164 polymorphism and inflammatory arthritis susceptibility in the overall population (G vs C, OR: 1.061, 95% CI= 0.933-1.207,*P*=0.365; GC+CC vs GG, OR: 0.919, 95% CI=0.762-1.110,*P*=0.381; CC vs GG+GC, OR: 0.935, 95% CI=0.821-1.065,*P*=0.310). After stratifying by region, it only showed the association between miRNA-146 rs2910164 polymorphism and inflammatory arthritis susceptibility in Middle East ([Figure 2](#fig2){ref-type="fig"}). This may be due to the differences in geographic region, ethnicity, and sample size.

3.4. Meta-Analysis of Association between miRNA-499 rs3746444 Polymorphism and Inflammatory Arthritis {#sec3.4}
-----------------------------------------------------------------------------------------------------

Meta-analysis indicated significant association between miRNA-499 rs3746444 polymorphism and inflammatory arthritis susceptibility in the overall population (C vs T, OR: 1.422, 95% CI= 1.159-1.745,*P*=0.001; TC +CC vs TT, OR: 1.409, 95% CI=1.072-1.852,*P*=0.014; CC vs TT+TC, OR: 1.872, 95% CI=1.420-2.467,*P*\<0.001). After stratifying by region, the association between miRNA-499 rs3746444 polymorphism and inflammatory arthritis susceptibility was still extant in Middle East ([Figure 3](#fig3){ref-type="fig"}). But, we did not find this association in Asia and North America.

3.5. Heterogeneity and Publication Bias {#sec3.5}
---------------------------------------

The results of heterogeneity test were shown in [Table 2](#tab2){ref-type="table"}. And the results of Begg\'s test and Egger\'s test were also shown in [Table 2](#tab2){ref-type="table"}. As for some studies that had heterogeneity (*I*^2^ \> 50%), the random-effects models were performed; others were analyzed by fixed-effects model. As for miRNA-499 rs3746444 polymorphism, the plot of sensitivity analysis was shown in [Figure 4](#fig4){ref-type="fig"}. And there was no significant evidence of publication bias found in the meta-analysis.

4. Discussion {#sec4}
=============

Both environmental factors and genetic factors are related to the development of inflammatory arthritis. As for miRNAs, it is reported that they are involved in cancers and autoimmune diseases \[[@B15], [@B21]\]. But some recent studies about miRNA-146/499 polymorphisms and inflammatory arthritis are inconsistent; it needs us to explore the real association between miRNA-146/499 polymorphisms and inflammatory arthritis by conducting this meta-analysis.

Present meta-analysis included 18 relevant studies, 9 only about miRNA-146 rs2910164, 3 only about miRNA-499 rs3746444, and 6 about both miRNA-146 rs2910164 and miRNA-499 rs3746444. There were 5 studies not met Hardy--Weinberg equilibrium; we did not exclude those 5 studies. We conducted subgroup analysis according to HWE and found that the results are similar ([Table 2](#tab2){ref-type="table"}).

Of course, there were some limitations in this meta-analysis. First, we searched literature based on English; it may cause language bias. Second, the number of included studies was not sufficient, which could not conduct comprehensive analysis. Third, our data of meta-analysis were from retrospective research, which may be related to the methodological deficiencies. Finally, our meta-analysis did not take the interactions between environmental factors and genetic factors into account. Therefore, the results should be interpreted with caution.

In conclusion, the present study indicates that miRNA-499 rs3746444 polymorphism is associated with inflammatory arthritis susceptibility. However, there is lack of association between miRNA-146 rs2910164 polymorphism and inflammatory arthritis susceptibility. But, we find miRNA-146 rs2910164 and miRNA-499 rs3746444 polymorphism are associated with inflammatory arthritis in Middle East. Therefore, it is necessary to conduct more large-sample and more high-quality studies to further validate our findings.
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###### 

The main features of included studies.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author               Year   Disease   Country        Region          Genotyping methods   Number of Cases   Number of controls   Characteristics of controls   Polymorphisms            NOS score
  -------------------- ------ --------- -------------- --------------- -------------------- ----------------- -------------------- ----------------------------- ------------------------ -----------
  Chatzikyriakidou A   2010   RA        Greece         Europe          PCR--RFLP            136               147                  Healthy                       rs2910164(miRNA-146)     6

                                                                                                                                                                                          

  Yang XK              2016   RA        China          Asia            TaqMan               386               576                  Healthy                       rs3746444(miRNA-499)     7

                                                                                                                                                                                          

  Singh S              2014   JIA-ERA   India          Asia            PCR--RFLP            150               216                  Healthy                       rs2910164(miRNA-146)     7

                                                                                                                                                                                          

  El-Shal AS           2013   RA        Egypt          Middle East     PCR--RFLP            217               245                  Healthy                       rs2910164(miRNA-146),\   6
                                                                                                                                                                 rs3746444(miRNA-499)     

                                                                                                                                                                                          

  Shaker OG            2018   RA        Egypt          Middle East     TaqMan               104               112                  Healthy                       rs2910164(miRNA-146),\   7
                                                                                                                                                                 rs3746444(miRNA-499)     

                                                                                                                                                                                          

  Hashemi M            2012   RA        Iran           Middle East     T-ARMS-PCR           104               110                  Healthy                       rs2910164(miRNA-146),\   6
                                                                                                                                                                 rs3746444(miRNA-499)     

                                                                                                                                                                                          

  Yang B               2010   RA        China          Asia            PCR--RFLP            208               240                  Healthy                       rs2910164(miRNA-146),\   7
                                                                                                                                                                 rs3746444(miRNA-499)     

                                                                                                                                                                                          

  Aleman-Avila I       2017   RA        Mexico         North America   TaqMan               412               486                  Healthy                       rs2910164(miRNA-146),\   7
                                                                                                                                                                 rs3746444(miRNA-499),\   
                                                                                                                                                                 rs11614913(miRNA-196)    

                                                                                                                                                                                          

  Zhou X               2015   RA        China          Asia            NA                   598               821                  NA                            rs2910164(miRNA-146)     5

                                                                                                                                                                                          

  Hassine HB           2017   RA        Tunisia        Middle East     PCR--RFLP            165               150                  Healthy                       rs2910164(miRNA-146)     6

                                                                                                                                                                                          

  Maharaj AB(1)        2018   PsA       South Africa   Africa          PCR--RFLP            84                62                   Healthy                       rs2910164(miRNA-146)     6

                                                                                                                                                                                          

  Maharaj AB(2)        2018   PsA       South Africa   Africa          PCR--RFLP            32                38                   Healthy                       rs2910164(miRNA-146)     6

                                                                                                                                                                                          

  Jimenez-Morales S    2012   JRA       Mexico         North America   TaqMan               210               531                  Healthy                       rs2910164(miRNA-146)     7

                                                                                                                                                                                          

  Ciccacci C           2016   RA        Italy          Europe          TaqMan               192               298                  Healthy                       rs2910164(miRNA-146)     7

                                                                                                                                                                                          

  Ayeldeen G           2018   RA        Egypt          Middle East     real-time PCR        52                56                   Healthy                       rs2910164(miRNA-146),\   6
                                                                                                                                                                 rs3746444(miRNA-499)     

                                                                                                                                                                                          

  Toraih EA            2016   RA        Egypt          Middle East     TaqMan               95                200                  Healthy                       rs3746444(miRNA-499),\   6
                                                                                                                                                                 rs11614913(miRNA-196)    

                                                                                                                                                                                          

  Fattah SA            2018   RA        Egypt          Middle East     PCR--RFLP            100               100                  Healthy                       rs3746444(miRNA-499)     6

                                                                                                                                                                                          

  Bogunia-Kubik K      2016   RA        Poland         Europe          PCR--RFLP            111               130                  Healthy                       rs2910164(miRNA-146)     6

                                                                                                                                                                                          

  Chatzikyriakidou A   2010   PsA       Greece         Europe          PCR--RFLP            29                66                   NA                            rs2910164(miRNA-146)     6
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

HWE: Hardy--Weinberg equilibrium; NOS: Newcastle-Ottawa Quality Assessment Scale.

###### 

The results of meta-analysis, heterogeneity test, and publication bias.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  polymorphism    Number of studies   Comparable genotype   No. of Cases/Controls   Test of association   Test of heterogeneity   Test of publication bias   Model                                       
  --------------- ------------------- --------------------- ----------------------- --------------------- ----------------------- -------------------------- ------- ------- ------- ------- ------- --- ---
  rs2910164\                                                                                                                                                                                              
  (miRNA-146)                                                                                                                                                                                            

  Overall         16                  G vs C                2802/3708               1.061(0.933-1.207)    0.365                   58.80%                     0.002   0.14    0.893   0.60    0.559   R   

  Region                                                                                                                                                                                                  

  Europe          4                   G vs C                468/641                 1.017(0..836-1.236)   0.868                   0.00%                      0.753   1.02    0.308   -2.93   0.100   F   

  Asia            3                   G vs C                956/1277                0.991(0.877-1.120)    0.890                   0.00%                      0.412   1.04    0.296   -1.89   0.309   F   

  Middle East     5                   G vs C                642/673                 1.449(1.229-1.709)    0.001                   47.30%                     0.108   0.24    0.806   0.53    0.630   F   

  Africa          2                   G vs C                116/100                 0.615(0.405-0.935)    0.023                   0.50%                      0.316   0.00    1.000   NA      NA      F   

  North America   2                   G vs C                620/1017                0.955(0.820-1.111)    0.551                   36.40%                     0.210   0.00    1.000   NA      NA      F   

  HWE                                                                                                                                                                                                     

  Y               13                  G vs C                2524/3359               1.053(0.916-1.211)    0.469                   61.90%                     0.002   0.18    0.855   0.99    0.344   R   

  Overall         16                  GC+CC\                2802/3708               0.919(0.762-1.110)    0.381                   57.20%                     0.002   -0.05   1.000   0.05    0.963   R   
                                      vs GG                                                                                                                                                              

  Region                                                                                                                                                                                                  

  Europe          4                   GC+CC\                468/641                 1.000(0.784-1.276)    0.998                   0.00%                      0.606   1.70    0.089   13.66   0.005   F   
                                      vs GG                                                                                                                                                              

  Asia            3                   GC+CC\                956/1277                0.980(0.795-1.209)    0.851                   0.00%                      0.869   0.00    1.000   0.16    0.896   F   
                                      vs GG                                                                                                                                                              

  Middle East     5                   GC+CC vs GG           642/673                 0.530(0.320-0.877)    0.014                   64.30%                     0.024   0.73    0.462   -0.99   0.394   R   

  Africa          2                   GC+CC vs GG           116/100                 1.915(1.107-3.314)    0.020                   49.40%                     0.160   0.00    1.000   NA      NA      F   

  North America   2                   GC+CC vs GG           620/1017                1.009(0.735-1.385)    0.956                   57.20%                     0.127   0.00    1.000   NA      NA      R   

  HWE                                                                                                                                                                                                     

  Y               13                  GC+CC vs GG           2524/3359               0.942(0.780-1.137)    0.532                   55.80%                     0.007   0.06    0.951   0.02    0.982   R   

  Overall         16                  CC vs GG+GC           2802/3708               0.935(0.821-1.065)    0.310                   34.60%                     0.086   1.22    0.224   0.98    0.343   F   

  Region                                                                                                                                                                                                  

  Europe          4                   CC vs GG+GC           468/641                 0.914(0.581-1.439)    0.699                   0.00%                      0.839   -0.34   1.000   0.23    0.837   F   

  Asia            3                   CC vs GG+GC           956/1277                1.149(0.803-1.645)    0.447                   59.10%                     0.087   1.04    0.296   2.69    0.227   R   

  Middle East     5                   CC vs GG+GC           642/673                 0.631(0.483-0.823)    0.001                   0.00%                      0.431   0.24    0.806   -0.60   0.590   F   

  Africa          2                   CC vs GG+GC           116/100                 2.211(0.674-7.256)    0.191                   0.00%                      0.581   0.00    1.000   NA      NA      F   

  North America   2                   CC vs GG+GC           620/1017                1.151(0.837-1.582)    0.387                   0.00%                      0.739   0.00    1.000   NA      NA      F   

  HWE                                                                                                                                                                                                     

  Y               13                  CC vs GG+GC           2524/3359               0.959(0.834-1.103)    0.556                   40.20%                     0.066   0.55    0.583   0.37    0.722   F   

  rs3746444\                                                                                                                                                                                              
  (miRNA-499)                                                                                                                                                                                            

  Overall         9                   C vs T                1678/2125               1.422(1.159-1.745)    0.001                   63.30%                     0.005   1.15    0.251   1.30    0.234   R   

  Region                                                                                                                                                                                                  

  Asia            2                   C vs T                594/816                 1.128(0.904-1.406)    0.286                   0.00%                      0.573   0.00    1.000   NA      NA      F   

  Middle East     6                   C vs T                672/823                 1.614(1.219-2.137)    0.001                   66.80%                     0.010   0.75    0.452   0.77    0.485   R   

  North America   1                   C vs T                412/486                 1.215(0.845-1.748)    0.294                   NA                         NA      NA      NA      NA      NA      F   

  HWE                                                                                                                                                                                                     

  Y               7                   C vs T                1479/1815               1.390(1.214-1.591)    0.001                   31.00%                     0.191   0.30    0.764   0.99    0.368   F   

  Overall         9                   TC+CC vs TT           1678/2125               1.409(1.072-1.852)    0.014                   67.50%                     0.002   0.10    0.917   1.03    0.335   R   

  Region                                                                                                                                                                                                  

  Asia            2                   TC+CC vs TT           594/816                 1.138(0.891-1.454)    0.301                   0.00%                      0.374   0.00    1.000   NA      NA      F   

  Middle East     6                   TC+CC vs TT           672/823                 1.634(1.062-2.513)    0.026                   73.40%                     0.002   0.75    0.452   0.10    0.924   R   

  North America   1                   TC+CC vs TT           412/486                 1.188(0.809-1.742)    0.379                   NA                         NA      NA      NA      NA      NA      F   

  HWE                                                                                                                                                                                                     

  Y               7                   TC+CC vs TT           1479/1815               1.399(1.190-1.645)    0.001                   38.20%                     0.138   0.00    1.000   1.11    0.319   F   

  Overall         9                   CC vs TT+TC           1678/2125               1.872(1.420-2.467)    0.001                   0.00%                      0.588   0.10    0.917   0.42    0.686   F   

  Region                                                                                                                                                                                                  

  Asia            2                   CC vs TT+TC           594/816                 1.224(0.551-2.717)    0.619                   0.00%                      0.495   0.00    1.000   NA      NA      F   

  Middle East     6                   CC vs TT+TC           672/823                 1.960(1.455-2.641)    0.001                   0.00%                      0.462   0.38    0.707   0.66    0.545   F   

  North America   1                   CC vs TT+TC           412/486                 3.557(0.369-34.331)   0.273                   NA                         NA      NA      NA      NA      NA      F   

  HWE                                                                                                                                                                                                     

  Y               7                   CC vs TT+TC           1479/1815               1.910(1.334-2.736)    0.001                   0.00%                      0.696   0.00    1.000   -0.21   0.840   F   
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

R: random-effects model; F: fixed-effects model; Y: yes (studies that suitable for HWE); *P*~H~: the value of *P* in the heterogeneity test.
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